281 related articles for article (PubMed ID: 20008298)
1. Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis.
Santos FP; Kantarjian HM; Jain N; Manshouri T; Thomas DA; Garcia-Manero G; Kennedy D; Estrov Z; Cortes J; Verstovsek S
Blood; 2010 Feb; 115(6):1131-6. PubMed ID: 20008298
[TBL] [Abstract][Full Text] [Related]
2. A phase 1 study of the Janus kinase 2 (JAK2)
Verstovsek S; Mesa RA; Salama ME; Li L; Pitou C; Nunes FP; Price GL; Giles JL; D'Souza DN; Walgren RA; Prchal JT
Leuk Res; 2017 Oct; 61():89-95. PubMed ID: 28934680
[TBL] [Abstract][Full Text] [Related]
3. Open-label study of oral CEP-701 (lestaurtinib) in patients with polycythaemia vera or essential thrombocythaemia with JAK2-V617F mutation.
Hexner E; Roboz G; Hoffman R; Luger S; Mascarenhas J; Carroll M; Clementi R; Bensen-Kennedy D; Moliterno A
Br J Haematol; 2014 Jan; 164(1):83-93. PubMed ID: 24903629
[TBL] [Abstract][Full Text] [Related]
4. Megakaryocytic morphology and clinical parameters in essential thrombocythemia, polycythemia vera, and primary myelofibrosis with and without JAK2 V617F.
Vytrva N; Stacher E; Regitnig P; Zinke-Cerwenka W; Hojas S; Hubmann E; Porwit A; Bjorkholm M; Hoefler G; Beham-Schmid C
Arch Pathol Lab Med; 2014 Sep; 138(9):1203-9. PubMed ID: 25171702
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.
Verstovsek S; Kantarjian H; Mesa RA; Pardanani AD; Cortes-Franco J; Thomas DA; Estrov Z; Fridman JS; Bradley EC; Erickson-Viitanen S; Vaddi K; Levy R; Tefferi A
N Engl J Med; 2010 Sep; 363(12):1117-27. PubMed ID: 20843246
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis.
Pardanani A; Gotlib JR; Jamieson C; Cortes JE; Talpaz M; Stone RM; Silverman MH; Gilliland DG; Shorr J; Tefferi A
J Clin Oncol; 2011 Mar; 29(7):789-96. PubMed ID: 21220608
[TBL] [Abstract][Full Text] [Related]
7. Phase II trial of panobinostat, an oral pan-deacetylase inhibitor in patients with primary myelofibrosis, post-essential thrombocythaemia, and post-polycythaemia vera myelofibrosis.
DeAngelo DJ; Mesa RA; Fiskus W; Tefferi A; Paley C; Wadleigh M; Ritchie EK; Snyder DS; Begna K; Ganguly S; Ondovik MS; Rine J; Bhalla KN
Br J Haematol; 2013 Aug; 162(3):326-35. PubMed ID: 23701016
[TBL] [Abstract][Full Text] [Related]
8. A phase II trial of tipifarnib in myelofibrosis: primary, post-polycythemia vera and post-essential thrombocythemia.
Mesa RA; Camoriano JK; Geyer SM; Wu W; Kaufmann SH; Rivera CE; Erlichman C; Wright J; Pardanani A; Lasho T; Finke C; Li CY; Tefferi A
Leukemia; 2007 Sep; 21(9):1964-70. PubMed ID: 17581608
[TBL] [Abstract][Full Text] [Related]
9. Emerging drugs for the therapy of primary and post essential thrombocythemia, post polycythemia vera myelofibrosis.
Mesa RA; Tefferi A
Expert Opin Emerg Drugs; 2009 Sep; 14(3):471-9. PubMed ID: 19552608
[TBL] [Abstract][Full Text] [Related]
10. JAK2 inhibitors for myeloproliferative neoplasms: what is next?
Bose P; Verstovsek S
Blood; 2017 Jul; 130(2):115-125. PubMed ID: 28500170
[TBL] [Abstract][Full Text] [Related]
11. Phase 2 study of gandotinib (LY2784544) in patients with myeloproliferative neoplasms.
Berdeja J; Palandri F; Baer MR; Quick D; Kiladjian JJ; Martinelli G; Verma A; Hamid O; Walgren R; Pitou C; Li PL; Gerds AT
Leuk Res; 2018 Aug; 71():82-88. PubMed ID: 30025280
[TBL] [Abstract][Full Text] [Related]
12. The diagnosis and management of polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the JAK2 V617F era.
Zhan H; Spivak JL
Clin Adv Hematol Oncol; 2009 May; 7(5):334-42. PubMed ID: 19521323
[TBL] [Abstract][Full Text] [Related]
13. Spleen deflation and beyond: the pros and cons of Janus kinase 2 inhibitor therapy for patients with myeloproliferative neoplasms.
Quintás-Cardama A; Verstovsek S
Cancer; 2012 Feb; 118(4):870-7. PubMed ID: 21766300
[TBL] [Abstract][Full Text] [Related]
14. Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study
Palandri F; Palumbo GA; Iurlo A; Polverelli N; Benevolo G; Breccia M; Abruzzese E; Tiribelli M; Bonifacio M; Tieghi A; Isidori A; Martino B; Sgherza N; D'Adda M; Bergamaschi M; Crugnola M; Cavazzini F; Bosi C; Binotto G; Auteri G; Latagliata R; Ibatici A; Scaffidi L; Penna D; Cattaneo D; Soci F; Trawinska M; Russo D; Cuneo A; Semenzato G; Di Raimondo F; Aversa F; Lemoli RM; Heidel F; Reggiani MLB; Bartoletti D; Cavo M; Catani L; Vianelli N
Semin Hematol; 2018 Oct; 55(4):248-255. PubMed ID: 30502854
[TBL] [Abstract][Full Text] [Related]
15. A phase I study of panobinostat and ruxolitinib in patients with primary myelofibrosis (PMF) and post--polycythemia vera/essential thrombocythemia myelofibrosis (post--PV/ET MF).
Mascarenhas J; Marcellino BK; Lu M; Kremyanskaya M; Fabris F; Sandy L; Mehrotra M; Houldsworth J; Najfeld V; El Jamal S; Petersen B; Moshier E; Hoffman R
Leuk Res; 2020 Jan; 88():106272. PubMed ID: 31778911
[TBL] [Abstract][Full Text] [Related]
16. Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib.
Bryan JC; Verstovsek S
Cancer Chemother Pharmacol; 2016 Jun; 77(6):1125-42. PubMed ID: 27017614
[TBL] [Abstract][Full Text] [Related]
17. JAK2 inhibition has different therapeutic effects according to myeloproliferative neoplasm development in mice.
Debeurme F; Lacout C; Moratal C; Bagley RG; Vainchenker W; Adrian F; Villeval JL
J Cell Mol Med; 2015 Nov; 19(11):2564-74. PubMed ID: 26176817
[TBL] [Abstract][Full Text] [Related]
18. A phase II study of panobinostat in patients with primary myelofibrosis (PMF) and post-polycythemia vera/essential thrombocythemia myelofibrosis (post-PV/ET MF).
Mascarenhas J; Sandy L; Lu M; Yoon J; Petersen B; Zhang D; Ye F; Newsom C; Najfeld V; Hochman T; Goldberg JD; Hoffman R
Leuk Res; 2017 Feb; 53():13-19. PubMed ID: 27930945
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of plitidepsin in patients with primary myelofibrosis and post polycythemia vera/essential thrombocythemia myelofibrosis: results of preclinical studies and a phase II clinical trial.
Pardanani A; Tefferi A; Guglielmelli P; Bogani C; Bartalucci N; Rodríguez J; Extremera S; Pérez I; Alfaro V; Vannucchi AM
Blood Cancer J; 2015 Mar; 5(3):e286. PubMed ID: 25768401
[TBL] [Abstract][Full Text] [Related]
20. A phase I study of panobinostat (LBH589) in patients with primary myelofibrosis (PMF) and post-polycythaemia vera/essential thrombocythaemia myelofibrosis (post-PV/ET MF).
Mascarenhas J; Lu M; Li T; Petersen B; Hochman T; Najfeld V; Goldberg JD; Hoffman R
Br J Haematol; 2013 Apr; 161(1):68-75. PubMed ID: 23330839
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
